NASDAQ:HCAT - Get Free Report ) have earned a consensus rating of "Moderate Buy" from the eleven brokerages that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $12.10.
Get Health Catalyst alerts:
Sign Up
Several analysts recently commented on HCAT shares. Evercore ISI decreased their price target on Health Catalyst from $11.00 to $10.00 and set an "outperform" rating on the stock in a research note on Friday, February 23rd. Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Friday, February 23rd. Piper Sandler reissued an "overweight" rating and set a $15.00 target price (down previously from $17.00) on shares of Health Catalyst in a research note on Friday, February 23rd. KeyCorp reissued a "sector weight" rating on shares of Health Catalyst in a report on Wednesday, April 10th. Finally, Guggenheim raised Health Catalyst from a "neutral" rating to a "buy" rating and set a $14.00 target price for the company in a research report on Friday, January 26th.
View Our Latest Report on Health Catalyst
Institutional Inflows and Outflows Large investors have recently made changes to their positions in the stock. Impax Asset Management Group plc lifted its holdings in Health Catalyst by 52.0% during the fourth quarter. Impax Asset Management Group plc now owns 1,754,475 shares of the company's stock valued at $16,246,000 after purchasing an additional 600,000 shares in the last quarter. Primecap Management Co. CA increased its stake in Health Catalyst by 86.3% in the 3rd quarter. Primecap Management Co. CA now owns 1,120,438 shares of the company's stock worth $11,339,000 after buying an additional 519,004 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Health Catalyst by 124.0% during the third quarter. Bank of New York Mellon Corp now owns 854,896 shares of the company's stock valued at $8,652,000 after acquiring an additional 473,323 shares during the period. Essex Investment Management Co. LLC purchased a new position in shares of Health Catalyst in the first quarter valued at about $1,848,000. Finally, ClariVest Asset Management LLC boosted its stake in shares of Health Catalyst by 303.9% in the first quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company's stock worth $2,126,000 after acquiring an additional 212,425 shares during the period. 85.00% of the stock is owned by hedge funds and other institutional investors.
Health Catalyst Trading Up 0.3 % Shares of HCAT stock traded up $0.02 during mid-day trading on Thursday, reaching $6.67. The company's stock had a trading volume of 1,190,289 shares, compared to its average volume of 633,545. The company's 50 day simple moving average is $7.05 and its 200-day simple moving average is $8.15. Health Catalyst has a 12-month low of $5.45 and a 12-month high of $14.37. The firm has a market capitalization of $393.73 million, a PE ratio of -3.18 and a beta of 1.32. The company has a quick ratio of 4.42, a current ratio of 4.42 and a debt-to-equity ratio of 0.62.
Health Catalyst (NASDAQ:HCAT - Get Free Report ) last released its earnings results on Thursday, February 22nd. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 12.19% and a negative net margin of 39.92%. The firm had revenue of $75.08 million during the quarter, compared to the consensus estimate of $73.67 million. On average, research analysts predict that Health Catalyst will post -0.47 EPS for the current fiscal year.
About Health Catalyst (
Get Free Report Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Featured Articles
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
